Acta Pharmaceuticals is a Boston, MA-based biopharmaceutical company developing therapies for early intervention and prevention of Alzheimer's disease. Its lead candidate, GSM-779690T, is a once-daily oral gamma-secretase modulator in Phase 1 testing that selectively lowers plaque-forming Aβ42 while promoting protective amyloid-beta peptides, built on some 25 years of research by scientific founder Dr. Rudolph E. Tanzi and the late Dr. Steven L. Wagner. Using the Alzheimer's-in-a-Dish human brain-cell models developed at Massachusetts General Hospital, the company also advances a combination-therapies program screening approved drugs and natural compounds.
1
Round
1
Industry
5
Tags
Oct 15, 2026
Latest raise
Funding activity · 1 round
Oct 15, 2026
$24M
Seed
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
